We are monitoring the impact of COVID-19 on Humira Market Get in touch with us for detailed analysis Know More
Share on

Global Humira Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type (Humira Syringe, Humira Pen), Application & Region – Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 9026
Pages: 120

Global Humira Market Size (2022 to 2027)

Globally, the size of the Humira market is expected to grow at a vibrant CAGR between 2022 to 2027.

Humira was initially approved in the United States and is now available in more than 60 countries. Over the years, technological advances and increased R & D activity for Humira biosimilars' development have created some growth opportunities for these drugs.

Humira is used for various diseases where the patient fails to respond to any other treatments. Humira is also known as adalimumab, and this is used in the form of injections under the skin. Physicians generally prescribe this medication only when a patient has no response with the other treatment procedures. Initially, it was approved by the U.S. government to use this medication for various diseases like rheumatoid arthritis, psoriatic arthritis, and others. Therefore, the market size is expected to grow tremendously during the forecast period.

MARKET DRIVERS:

An increasing number of patients with diseases due to lifestyle changes and the rise in capital income in developed and developing countries are primary factors that boost the global Humira market’s growth rate.

The forefront of driving the global Humira market is the increase in global arthritis. It, in turn, is mainly due to the rapid growth of the elderly population. Most women have arthritis in old age due to the loss of calcium in the body. Sedentary lifestyles have also led to the development of another condition called arthritis or psoriasis. They all contribute to consuming the product and other factors, such as an increased prevalence of Crohn's disease and ulcerative colitis. Also, factors such as improved disease diagnostics and strong support for effective biopharmaceuticals is forecasted to drive the growth of the global Humira market. However, due to its biological properties, Humira is an expensive drug. Monthly costs range from USD 2,000 to USD 3,000, which is one factor that hinders the market growth. On the other hand, the emergence of the latest technologies and the launch of various treatment procedures in favor of the end-users is likely to bolster the development of the market. In addition, increasing support from the various governments through investments is to surge growth opportunities for the market.

Key market players are actively investing to take advantage of untapped opportunities in Latin America and the Asia-Pacific region, and opportunities for market growth will remain soon. Furthermore, after the blockbuster drug patent expired, Humira's entry provided new opportunities for key players in the market.

MARKET RESTRAINTS:

However, the lack of skilled persons in treating the disease with proper dosage form slightly declines the Humira market's growth. High cost for treatment procedures remained a challenging factor for the market. The high price of clinical trials and R&D is a significant challenge witnessed by market operators. Despite high R&D spending, manufacturers need to keep their products low, further limiting growth opportunities in the global Humira market. Lack of reimbursement for biopharmaceutical treatments also harms the market.

Impact of COVID-19 on the global Humira market:

The most recent COVID-19 outbreak started in Wuhan, China, in December 2019 and has rapidly spread worldwide since then. As of March 2020, China, Italy, Iran, Spain, France, Germany, and the United States were the countries with the highest number of positive cases and reported deaths. Due to the lockdowns, travel bans, and company closures, the COVID-19 pandemic has impacted economies and businesses in several countries. With the presence of the largest raw material suppliers, China is the global industrial powerhouse. However, due to the factory closures, supply chain obstacles, and the global economic collapse, the regular market breakdown caused by COVID-19 is also harming the expansion of the market. However, the situation is expected to change, and the market’s growth will fall back to its regular position.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2027

Base Year

2021

Forecast Period

2022 to 2027

Segments Analysed

By Type, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

Companies Analysed

Pfizer, Amgen, Novartis AG, Boehringer Ingelheim GmbH, Mylan N.V., and AbbVie among others.

 

This research report on the global Humira market has been segmented and sub-segmented based on type, application, and region.

Humira Market - By Type:

  • Humira Syringe
  • Humira Pen

Based on type, the Humira syringes segment is forecasted to account for the most significant share in the global Humira market during the forecast period due to the rising elderly population globally.

Humira Market - By Application:

  • Ankylosing Spondylitis
  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Others

Based on the application, the Ankylosing spondylitis application segment is estimated to register the majority of the share in the global Humira market.

Humira Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Geographically, the North American Humira market had the largest share in the global Humira market in 2020 with the latest technology developments and various innovative drugs to enhance treatment procedures. In addition, factors such as the availability of advanced healthcare facilities, technological advancements, and the launch of numerous revolutionary pharmaceuticals are accelerating the North American regional market’s growth rate. As a result, the United States was the largest market in the North American market in 2020, accounting for a market share of 65%.

Globally, the European Humira market was the second-largest regional market in 2020 and accounted for around 30% of the share. Also, with the surge in Crohn’s disease cases. As a result, Europe has been gradually growing over the last few years. The developing countries such as the United Kingdom and Germany dominate the Humira market owing to the growing scale of pharmaceutical firms and increasing desire to enhance productivity in the European region. Europe has been growing steadily over the past few years with the rising scale of pharmaceutical companies and increasing demand to expand productivity.

The APAC Humira market is one of the fastest-growing regions in the global market and is quickly catching up to North America in terms of market share. China, India, Japan is driving the growth of the Humira market in the Asia Pacific. 

The most prosperous countries in Latin America for the Humira market are Brazil, Mexico, and Argentina. Brazil is the only one of these countries with a biopharmaceutical regulatory policy, making it a key market. Brazilian patients are also becoming more conscious of biopharmaceutical choices, propelling Humira to the top of the market.

The Middle East and Africa are inclined to substantial growth opportunities during the forecast period. 

KEY MARKET PLAYERS:

A few promising companies operating in the global Humira market profiled in this report are Pfizer, Amgen, Novartis AG, Boehringer Ingelheim GmbH, Mylan N.V., and AbbVie.

RECENT MARKET DEVELOPMENTS:

  • Humira’s decline in 2019 was expected, as it was the first year the medicine faced biosimilar competition in Europe. As a result, overseas sales dropped by 31%. On the other hand, Humira resisted the international erosion and remained a growing force in the United States, which accounted for $16.1 billion of its sales this year, up from $14.9 billion in 2019.
  • Cadila Pharmaceuticals announced the launch of Cadalimab, an adalimumab biosimilar to AbbVie’s Humira, in India in August 2020.
  • AbbVie stated in May 2019 that it had settled its patent battle with Boehringer Ingelheim over adalimumab. It is a significant settlement because it resolves all Humira-related patent litigation in the United States and opens the door for another biosimilar producer wishing to enter the country.
  • In November 2018, AbbVie Inc. announced a patent license agreement with Pfizer Inc for Humira and adalimumab. According to the terms of the deal, AbbVie Inc. awarded Pfizer a non-exclusive license for Humira. As a result of this deal, the company was able to grow its adalimumab market around the globe.
  • In 2018, Hetero Drugs Ltd. Launched its biosimilar Humira, marketed as Mabura, while Glenmark Pharmaceuticals Ltd. Signed a licensing agreement with Zydus Cadila to create another adalimumab brand, Adaly. Cipla Ltd. Has since entered the race with Plamumab, an in-licensed variant of adalimumab. Some internet pharmacies also list Envira (adalimumab) from local manufacturer Emcure Pharmaceuticals Ltd., though specifics were not immediately available. Humira, the original branded product.
  • In September 2016, Amgen got FDA clearance for AMJEVITA, which is authorized to treat all inflammatory diseases, just like Humira. Because of this product approval, the company has risen to the top of the biotechnology market.
  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
        1. Secondary Research
        2. Primary Research
        3. Econometric Modelling
        4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Type
      1. humira syringe
      2. humira pen
      3. Y-o-Y Growth Analysis, By Type
      4. Market Attractiveness Analysis, By Type
      5. Market Share Analysis, By Type
    2. By Application
      1. ankylosing spondylitis
      2. rheumatoid arthritis
      3. crohn’s disease
      4. others
      5. Y-o-Y Growth Analysis, By Application
      6. Market Attractiveness Analysis, By Application
      7. Market Share Analysis, By Application
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Type
        3. By Application
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Type
        3. By Application
      5. Market Share Analysis      
        1. By Geographical Area
        2. By Type
        3. By Application
    2. North America
      1. Introduction
      2. US
      3. Canada
    3. Europe
      1. Introduction
      2. UK
      3. France
      4. Spain
      5. Germany
      6. Italy
    4. Asia-Pacific
      1. Introduction
      2. India
      3. China
      4. Japan
      5. South Korea
      6. Australia
    5. Latin America
      1. Introduction
      2. Brazil
      3. Argentina
      4. Mexico
    6. Middle East & Africa
      1. Introduction
      2. Middle East
      3. Africa
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Pfizer Inc.
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. Amgen
    3. Novartis AG
    4. Boehringer Ingelheim GmbH
    5. Mylan N.V.
    6. AbbVie
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  1. Global Humira Market, By Region, From 2022 - 2027 (USD Billion)
  2. Global Humira Market, By Type, From 2022 - 2027 (USD Billion)
  3. Global Humira Syringe Market, By Region, From 2022 - 2027 (USD Billion)
  4. Global Humira Pen Market, By Region, From 2022 - 2027 (USD Billion)
  5. Global Humira Market, By Application, From 2022 - 2027 (USD Billion)
  6. Global Ankylosing Spondylitis Market, By Region, From 2022 - 2027 (USD Billion)
  7. Global Rheumatoid Arthritis Market, By Region, From 2022 - 2027 (USD Billion)
  8. Global Crohn’s Disease Market, By Region, From 2022 - 2027 (USD Billion)
  9. Global Others Market, By Region, From 2022 - 2027 (USD Billion)
  10. North America Humira Market, By Type, From 2022 - 2027 (USD Billion)
  11. North America Humira Syringe Market, By Region, From 2022 - 2027 (USD Billion)
  12. North America Humira Pen Market, By Region, From 2022 - 2027 (USD Billion)
  13. North America Humira Market, By Application, From 2022 - 2027 (USD Billion)
  14. North America Ankylosing Spondylitis Market, By Region, From 2022 - 2027 (USD Billion)
  15. North America Rheumatoid Arthritis Market, By Region, From 2022 - 2027 (USD Billion)
  16. North America Crohn’s Disease Market, By Region, From 2022 - 2027 (USD Billion)
  17. North America Others Market, By Region, From 2022 - 2027 (USD Billion)
  18. United States Humira Market, By Type, From 2022 - 2027 (USD Billion)
  19. United States Humira Market, By Application, From 2022 - 2027 (USD Billion)
  20. Canada Humira Market, By Type, From 2022 - 2027 (USD Billion)
  21. Canada Humira Market, By Application, From 2022 - 2027 (USD Billion)
  22. Europe Humira Market, By Type, From 2022 - 2027 (USD Billion)
  23. Europe Humira Syringe Market, By Region, From 2022 - 2027 (USD Billion)
  24. Europe Humira Pen Market, By Region, From 2022 - 2027 (USD Billion)
  25. Europe Humira Market, By Application, From 2022 - 2027 (USD Billion)
  26. Europe Ankylosing Spondylitis Market, By Region, From 2022 - 2027 (USD Billion)
  27. Europe Rheumatoid Arthritis Market, By Region, From 2022 - 2027 (USD Billion)
  28. Europe Crohn’s Disease Market, By Region, From 2022 - 2027 (USD Billion)
  29. Europe Others Market, By Region, From 2022 - 2027 (USD Billion)
  30. U.K. Humira Market, By Type, From 2022 - 2027 (USD Billion)
  31. U.K. Humira Market, By Application, From 2022 - 2027 (USD Billion)
  32. Germany Humira Market, By Type, From 2022 - 2027 (USD Billion)
  33. Germany Humira Market, By Application, From 2022 - 2027 (USD Billion)
  34. France Humira Market, By Type, From 2022 - 2027 (USD Billion)
  35. France Humira Market, By Application, From 2022 - 2027 (USD Billion)
  36. Italy Humira Market, By Type, From 2022 - 2027 (USD Billion)
  37. Italy Humira Market, By Application, From 2022 - 2027 (USD Billion)
  38. Spain Humira Market, By Type, From 2022 - 2027 (USD Billion)
  39. Spain Humira Market, By Application, From 2022 - 2027 (USD Billion)
  40. Asia Pacific Humira Market, By Type, From 2022 - 2027 (USD Billion)
  41. Asia Pacific Humira Syringe Market, By Region, From 2022 - 2027 (USD Billion)
  42. Asia Pacific Humira Pen Market, By Region, From 2022 - 2027 (USD Billion)
  43. Asia Pacific Humira Market, By Application, From 2022 - 2027 (USD Billion)
  44. Asia Pacific Ankylosing Spondylitis Market, By Region, From 2022 - 2027 (USD Billion)
  45. Asia Pacific Rheumatoid Arthritis Market, By Region, From 2022 - 2027 (USD Billion)
  46. Asia Pacific Crohn’s Disease Market, By Region, From 2022 - 2027 (USD Billion)
  47. Asia Pacific Others Market, By Region, From 2022 - 2027 (USD Billion)
  48. Japan Humira Market, By Type, From 2022 - 2027 (USD Billion)
  49. Japan Humira Market, By Application, From 2022 - 2027 (USD Billion)
  50. China Humira Market, By Type, From 2022 - 2027 (USD Billion)
  51. China Humira Market, By Application, From 2022 - 2027 (USD Billion)
  52. India Humira Market, By Type, From 2022 - 2027 (USD Billion)
  53. India Humira Market, By Application, From 2022 - 2027 (USD Billion)
  54. Australia Humira Market, By Type, From 2022 - 2027 (USD Billion)
  55. Australia Humira Market, By Application, From 2022 - 2027 (USD Billion)
  56. South Korea Humira Market, By Type, From 2022 - 2027 (USD Billion)
  57. South Korea Humira Market, By Application, From 2022 - 2027 (USD Billion)
  58. Latin America Humira Market, By Type, From 2022 - 2027 (USD Billion)
  59. Latin America Humira Syringe Market, By Region, From 2022 - 2027 (USD Billion)
  60. Latin America Humira Pen Market, By Region, From 2022 - 2027 (USD Billion)
  61. Latin America Humira Market, By Application, From 2022 - 2027 (USD Billion)
  62. Latin America Ankylosing Spondylitis Market, By Region, From 2022 - 2027 (USD Billion)
  63. Latin America Rheumatoid Arthritis Market, By Region, From 2022 - 2027 (USD Billion)
  64. Latin America Crohn’s Disease Market, By Region, From 2022 - 2027 (USD Billion)
  65. Latin America Others Market, By Region, From 2022 - 2027 (USD Billion)
  66. Brazil Humira Market, By Type, From 2022 - 2027 (USD Billion)
  67. Brazil Humira Market, By Application, From 2022 - 2027 (USD Billion)
  68. Argentina Humira Market, By Type, From 2022 - 2027 (USD Billion)
  69. Argentina Humira Market, By Application, From 2022 - 2027 (USD Billion)
  70. Mexico Humira Market, By Type, From 2022 - 2027 (USD Billion)
  71. Mexico Humira Market, By Application, From 2022 - 2027 (USD Billion)
  72. Rest of Latin America Humira Market, By Type, From 2022 - 2027 (USD Billion)
  73. Rest of Latin America Humira Market, By Application, From 2022 - 2027 (USD Billion)
  74. Middle East and Africa Humira Market, By Type, From 2022 - 2027 (USD Billion)
  75. Middle East and Africa Humira Syringe Market, By Region, From 2022 - 2027 (USD Billion)
  76. Middle East and Africa Humira Pen Market, By Region, From 2022 - 2027 (USD Billion)
  77. Middle East and Africa Humira Market, By Application, From 2022 - 2027 (USD Billion)
  78. Middle East and Africa Ankylosing Spondylitis Market, By Region, From 2022 - 2027 (USD Billion)
  79. Middle East and Africa Rheumatoid Arthritis Market, By Region, From 2022 - 2027 (USD Billion)
  80. Middle East and Africa Crohn’s Disease Market, By Region, From 2022 - 2027 (USD Billion)
  81. Middle East and Africa Others Market, By Region, From 2022 - 2027 (USD Billion)
  82. Middle East Humira Market, By Type, From 2022 - 2027 (USD Billion)
  83. Middle East Humira Market, By Application, From 2022 - 2027 (USD Billion)
  84. Africa Humira Market, By Type, From 2022 - 2027 (USD Billion)
  85. Africa Humira Market, By Application, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

PURCHASE OPTIONS

excel
$

4255


pdf excel
$

7355


pdf excel powerbi
$

8455


excel
$

2500

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 4255

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample